natgillin/translations-raw huggingface dataset:
In a clinical pharmacology trial, in adults and adolescents, in which desloratadine was administered to adults at a dose of 45 mg daily (nine times the clinical dose) for ten days, no prolongation of QTc interval was seen.
V drugem kliničnem farmakološkem preskušanju pri odraslih in mladostnikih, pri katerem so odrasli jemali desloratadin v odmerku 45 mg na dan (9-kratni klinični odmerek) 10 dni, niso opažali podaljšanja intervala QTc.
Regarding the duration of treatment, your physician will determine the type of allergic rhinitis you are suffering from and will determine for how long you should take Azomyr.
Kar zadeva trajanje zdravljenja, bo vaš zdravnik najprej ugotovil vrsto alergijskega rinitisa, ki jo imate, in na podlagi tega določil, kako dolgo naj bi jemali zdravilo Azomyr.
Azomyr contains lactose
Zdravilo Azomyr vsebuje laktozo
Azomyr oral solution with food, drink and alcohol Azomyr may be taken with or without a meal.
Zdravilo Azomyr peroralna raztopina skupaj s hrano, pijačo in alkoholom Zdravilo Azomyr se lahko jemlje s hrano ali brez nje.
Azomyr was effective in alleviating the burden of seasonal allergic rhinitis as shown by the total score of the rhino-conjunctivitis quality of life questionnaire.
Zdravilo Azomyr je učinkovito ublažilo težave, povezane s sezonskim alergijskim rinitisom, kar so pokazali skupni rezultati vprašalnika o kakovosti življenja bolnikov z rinitisom in konjunktivitisom.
- The active substance is desloratadine 0.5 mg/ml - The other ingredients of the oral solution are sorbitol, propylene glycol, sucralose E 955, hypromellose 2910, sodium citrate dihydrate, natural and artificial flavour (bubblegum), citric acid anhydrous, disodium edetate and purified water.
- Zdravilna učinkovina je desloratadin 0,5 mg/ml - Pomožne snovi v peroralni raztopini so sorbitol, propilenglikol, sukraloza E 955, hipromeloza 2910, natrijev citrat dihidrat, naravna in umetna aroma (žvečilni gumi), brezvodna citronska kislina, dinatrijev edetat in prečiščena voda.
Azomyr 0.5 mg/ml oral solution desloratadine
Azomyr 0,5 mg/ml peroralna raztopina desloratadin
Azomyr is supplied in blisters comprised of laminate blister film with foil lidding.
Azomyr je na voljo v laminatnih pretisnih omotih, ki ga sestavljata film pretisnega, omota in folija, ki ga prekriva.
Azomyr orodispersible tablet is also used to relieve the symptoms associated with urticaria (a skin condition caused by an allergy).
Zdravilo Azomyr orodisperzibilna tableta se uporablja tudi za lajšanje simptomov urtikarije (težave s kožo zaradi alergije).
Azomyr oral solution contains sorbitol.
Zdravilo Azomyr peroralna raztopina vsebuje sorbitol Azomyr peroralna raztopina vsebuje sorbitol.
Azomyr is indicated in adults and adolescents aged 12 years and older for the relief of symptoms associated with: - allergic rhinitis (see section 5.1) - urticaria (see section 5.1)
Zdravilo Azomyr je indicirano pri odraslih in mladostnikih, starih 12 let in več, za lajšanje simptomov: - alergijskega rinitisa (glejte poglavje 5.1) - urtikarije (glejte poglavje 5.1)
Azomyr tablets given at a single daily dose of 7.5 mg to adults and adolescents did not affect psychomotor performance in clinical trials.
V kliničnih preskušanjih zdravilo Azomyr v enem dnevnem odmerku 7,5 mg pri odraslih in mladostnikih ni vplivalo na psihomotorične sposobnosti bolnikov.
How to take Azomyr orodispersible tablet
Kako jemati zdravilo Azomyr orodisperzibilna tableta
Azomyr orodispersible tablet is packed in unit dose blisters in packs of 5, 6, 10, 12, 15, 18, 20, 30, 50, 60, 90 and 100 doses of orodispersible tablet.
Azomyr orodisperzibilne tablete so na voljo v pretisnih omotih po 5, 6, 10, 12, 15, 18, 20, 30, 50, 60, 90 in 100 orodisperzibilnih tablet.
In clinical trials in a range of indications including allergic rhinitis and chronic idiopathic urticaria, at the recommended dose of 5 mg daily, undesirable effects with Azomyr tablets were reported in 3 % of patients in excess of those treated with placebo.
V kliničnih preskušanjih pri različnih indikacijah za uporabo zdravila, vključno z alergijskim rinitisom in kronično idiopatsko urtikarijo, so pri priporočenem odmerku 5 mg na dan o neželenih učinkih tablet Azomyr poročali pri 3 % bolnikov več kot pri tistih, ki so bili zdravljeni s placebom.
The safety and efficacy of Azomyr 5 mg film-coated tablets in children below the age of 12 years have not been established.
Varnost in učinkovitost zdravila Azomyr 5 mg filmsko obložene tablete pri otrocih, mlajših od 12 let, nista bili dokazani.
In a multiple dose clinical trial, in adults and adolescents, in which up to 20 mg of desloratadine was administered daily for 14 days, no statistically or clinically relevant cardiovascular effect was observed.
V kliničnem preskušanju večkratnega odmerjanja zdravila pri odraslih in mladostnikih, pri katerem so preiskovanci prejemali do 20 mg desloratadina na dan v času 14 dni, niso opažali nobenih statistično značilnih ali klinično pomembnih učinkov tega zdravila na srce ali ožilje.
The safety and efficacy of Azomyr 2.5 mg orodispersible tablets in children below the age of 6 years have not been established.
Varnost in učinkovitost zdravila Azomyr 2,5 mg orodisperzibilne tablete pri otrocih, mlajših od 6 let, nista bili dokazani.
At the recommended dose, in clinical trials involving adults and adolescents in a range of indications including allergic rhinitis and chronic idiopathic urticaria, undesirable effects with Azomyr were reported in 3 % of patients in excess of those treated with placebo.
V kliničnih preskušanjih pri odraslih in mladostnikih za različne indikacije, vključno z alergijskim rinitisom in kronično idiopatsko urtikarijo, so pri priporočenem odmerku o neželenih učinkih zdravila Azomyr poročali pri 3 % bolnikov več kot pri tistih, ki so bili zdravljeni s placebom.
In adult and adolescent patients with allergic rhinitis, Azomyr tablets were effective in relieving symptoms such as sneezing, nasal discharge and itching, as well as ocular itching, tearing and redness, and itching of palate.
Pri odraslih in mladostnikih z alergijskim rinitisom zdravilo Azomyr tablete učinkovito lajša simptome, kakor so kihanje, iztok iz nosa in srbenje, pa tudi srbenje oči, solzenje in vnetje očesne veznice ter srbenje ustnega neba.
The safety and efficacy of Azomyr 0.5 mg/ml oral solution in children below the age of 1 year have not been established.
Varnost in učinkovitost zdravila Azomyr 0,5 mg/ml peroralna raztopina pri otrocih, mlajših od 1 leta, nista bili dokazani.
What Azomyr oral solution is and what it is used for What you need to know before you take Azomyr oral solution How to take Azomyr oral solution Possible side effects
Kaj je zdravilo Azomyr in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Azomyr Kako jemati zdravilo Azomyr Možni neželeni učinki
In clinical trials in a range of indications including allergic rhinitis and chronic idiopathic urticaria, at the recommended dose of 5 mg daily, undesirable effects with Azomyr were reported in 3 % of patients in excess of those treated with placebo.
V kliničnih preskušanjih pri različnih indikacijah za uporabo zdravila, vključno z alergijskim rinitisom in kronično idiopatsko urtikarijo, so pri priporočenem odmerku 5 mg na dan o neželenih učinkih zdravila Azomyr poročali pri 3 % bolnikov več kot pri tistih, ki so bili zdravljeni s placebom.
How Azomyr works
Kako deluje zdravilo Azomyr
Azomyr oral solution is also used to relieve the symptoms associated with urticaria (a skin condition caused by an allergy).
Zdravilo Azomyr se uporablja tudi za lajšanje simptomov urtikarije (težave s kožo zaradi alergije).
How to take Azomyr
Kako jemati zdravilo Azomyr
Azomyr tablets given at a single daily dose of 7.5 mg did not affect psychomotor performance in clinical trials.
V kliničnih preskušanjih tablete Azomyr v enem dnevnem odmerku 7,5 mg niso vplivale na psihomotorične sposobnosti bolnikov.
This product contains 1.4 mg of phenylalanine per 2.5 mg dose of Azomyr orodispersible tablet.
Azomyr orodisperzibilne tablete vsebujejo 1,4 mg fenilalanina na 2,5 mg odmerek zdravila.
Azomyr 0.5 mg/ml oral solution
Azomyr 0,5 mg/ml peroralna raztopina
Azomyr is an antiallergy medicine that does not make you drowsy.
Zdravilo Azomyr je zdravilo proti alergiji, ki ne povzroča zaspanosti.
How to store Azomyr oral solution Contents of the pack and other information
Shranjevanje zdravila Azomyr peroralna raztopina Vsebina pakiranja in dodatne informacije
Clinical efficacy and safety In a multiple dose trial, Azomyr orodispersible tablets were well tolerated.
V preskušanju večkratnega odmerjanja so bolniki zdravilo Azomyr orodisperzibilne tablete dobro prenašali.
The safety and efficacy of Azomyr 5 mg orodispersible tablets in children below the age of 12 years have not been established.
Varnost in učinkovitost zdravila Azomyr 5 mg orodisperzibilne tablete pri otrocih, mlajših od 12 let, nista bili dokazani.
What Azomyr looks like and contents of the pack
Izgled zdravila Azomyr in vsebina pakiranja
If you forget to take Azomyr oral solution
Če ste prenehali jemati zdravilo Azomyr
What Azomyr contains
Kaj vsebuje zdravilo Azomyr
In patients with allergic rhinitis, Azomyr was effective in relieving symptoms such as sneezing, nasal discharge and itching, as well as ocular itching, tearing and redness, and itching of palate.
Pri bolnikih z alergijskim rinitisom zdravilo Azomyr učinkovito lajša simptome, kakor so kihanje, iztok iz nosa in srbenje, pa tudi srbenje oči, solzenje in vnetje očesne veznice ter srbenje ustnega neba.
This product contains 2.9 mg of phenylalanine per 5 mg dose of Azomyr orodispersible tablet.
Azomyr orodisperzibilne tablete vsebujejo 2,9 mg fenilalanina na 5 mg odmerek zdravila.
What Azomyr orodispersible tablet looks like and contents of the pack
Izgled zdravila Azomyr orodisperzibilna tableta in vsebina pakiranja
In patients with allergic rhinitis, Azomyr tablets were effective in relieving symptoms such as sneezing, nasal discharge and itching, as well as ocular itching, tearing and redness, and itching of palate.
Pri bolnikih z alergijskim rinitisom tablete Azomyr učinkovito lajšajo simptome, kakor so kihanje, iztok iz nosa in srbenje, pa tudi srbenje oči, solzenje in vnetje očesne veznice ter srbenje ustnega neba.
Azomyr 5 mg film-coated tablets
Azomyr 5 mg filmsko obložene tablete
Do not take Azomyr orodispersible tablet - if you are allergic to desloratadine, or any of the other ingredients of this medicine (listed in section 6) or to loratadine.
Ne uporabljajte zdravila Azomyr orodisperzibilna tableta - če ste alergični na desloratadin ali katero koli sestavino tega zdravila (navedeno v poglavju 6)
Azomyr given at a single daily dose of 7.5 mg did not affect psychomotor performance in clinical trials.
V kliničnih preskušanjih zdravilo Azomyr v enem dnevnem odmerku 7,5 mg ni vplivalo na psihomotorične sposobnosti bolnikov.
Do not take Azomyr oral solution - if you are allergic to desloratadine, or to any of the other ingredients of this medicine (listed in section 6) or to loratadine.
Ne uporabljajte zdravila Azomyr - če ste alergični na desloratadin ali katero koli sestavino tega zdravila (navedeno v poglavju 6)
Azomyr oral solution is available in bottles of 30, 50, 60, 100, 120, 150, 225 and 300 ml, with a childproof cap. For all packages except the 150 ml bottle, a measuring spoon is provided, marked for doses of 2.5 ml and 5 ml.
Azomyr peroralna raztopina je na voljo v stekleničkah po 30, 50, 60, 100, 120, 150, 225 in 300 ml, z zaporko, varno za otroke.
Azomyr 5 mg film-coated tablets desloratadine
Azomyr 5 mg filmsko obložene tablete desloratadin
What Azomyr orodispersible tablet contains
Kaj vsebuje zdravilo Azomyr orodisperzibilna tableta
Azomyr 2.5 mg orodispersible tablets desloratadine
Azomyr 2,5 mg orodisperzibilne tablete desloratadin
Azomyr 2.5 mg orodispersible tablet
Azomyr 2,5 mg orodisperzibilna tableta
How to store Azomyr
Shranjevanje zdravila Azomyr
Azomyr orodispersible tablet relieves symptoms associated with allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites) in adults, adolescents and children 6 years of age and older.
Zdravilo Azomyr orodisperzibilna tableta lajša simptome alergijskega rinitisa (vnetje nosnih poti zaradi alergije, na primer seneni nahod ali alergija na pršice) pri odraslih, mladostnikih in otrocih, starih 6 let in več.
Azomyr oral solution relieves symptoms associated with allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites) in adults, adolescents and children 1 year of age and older.
Zdravilo Azomyr peroralna raztopina lajša simptome alergijskega rinitisa (vnetje nosnih poti zaradi alergije, na primer seneni nahod ali alergija na pršice) pri odraslih, mladostnikih in otrocih, starih 1 leto in več.
Azomyr 2.5 mg orodispersible tablets
Azomyr 2,5 mg orodisperzibilne tablete
Azomyr orodispersible tablet relieves symptoms associated with allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites) in adults and adolescents 12 years of age and older.
Zdravilo Azomyr orodisperzibilna tableta lajša simptome alergijskega rinitisa (vnetje nosnih poti zaradi alergije, na primer seneni nahod ali alergija na pršice) pri odraslih in mladostnikih, starih 12 let in več.
Azomyr relieves symptoms associated with allergic rhinitis (inflammation of the nasal passages caused by an allergy, for example, hay fever or allergy to dust mites) in adults and adolescents 12 years of age and older.
Zdravilo Azomyr lajša simptome alergijskega rinitisa (vnetje nosnih poti zaradi alergije, na primer seneni nahod ali alergija na pršice) pri odraslih in mladostnikih, starih 12 let in več.
Azomyr 5 mg orodispersible tablet
Azomyr 5 mg orodisperzibilna tableta
Azomyr 5 mg orodispersible tablets
Azomyr 5 mg orodisperzibilne tablete
The recommended dose is 2.5 ml (½ of a 5 ml spoonful) of oral solution once a day.
Priporočeni odmerek zdravila Azomyr je 10 ml (5 mg) peroralne raztopine enkrat na dan.
Azomyr 5 mg orodispersible tablets desloratadine
Azomyr 5 mg orodisperzibilne tablete desloratadin
How to store Azomyr orodispersible tablet
Shranjevanje zdravila Azomyr orodisperzibilna tableta
What measures are being taken to ensure the safe and effective use of Ledaga?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Ledaga?
This means that it is similar to a ‘reference medicine' (in this case Caryolysine) containing the same active substance and used for the same purpose.
To pomeni, da je podobno „referenčnemu zdravilu“ (v tem primeru zdravilu Caryolysine), ki vsebuje enako zdravilno učinkovino in se ga uporablja v enake namene.
Ledaga was effective in 58% of patients (76 patients out of 130) after at least 6 months of treatment compared with 48% of patients (62 out of 130) using the ointment.
Zdravilo Ledaga je bilo po vsaj šestih mesecih zdravljenja učinkovito pri 58 % (76 od 130) bolnikov v primerjavi z 48 % (62 od 130) bolnikov, ki so uporabljali mazilo.
This is a summary of the European public assessment report (EPAR) for Ledaga.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Ledaga.
The most common side effects with Ledaga (which may affect more than 1 in 10 people) are dermatitis (skin inflammation with reddening, rash, pain and burning sensation), skin infection and itching.
Najpogostejši neželeni učinki zdravila Ledaga (ki lahko prizadenejo več kot 1 osebo od 10 ) so dermatitis (vnetje kože z rdečico, izpuščaji, bolečinami in pekočim občutkom), okužba kože in srbenje.
Effectiveness was measured as complete or partial improvement in the ‘CAILS' score, which takes into account different features of the cancer, such as the size and appearance of the skin damage.
Učinkovitost je bila izmerjena kot popolno ali delno izboljšanje po sestavljeni oceni indeksa resnosti poškodb (CAILS), ki upošteva različne lastnosti raka, kot sta obseg in videz poškodb na koži.
Alkylating agents work by attaching to the DNA of cells while the cells are dividing.
Alkilirajoče učinkovine delujejo tako, da se pritrdijo na DNK celic, medtem ko se celice delijo.
Treatment should be stopped if patients develop blisters or open sores.
Zdravljenje je treba prekiniti, če se pri bolnikih razvijejo mehurji ali odprte rane.
What are the risks associated with Ledaga?
Kakšna so tveganja, povezana z zdravilom Ledaga?
The company that markets Ledaga will supply materials to prevent accidental contact with the medicine, especially in the eye and the inside of the nose and mouth.
Družba, ki trži zdravilo Ledaga, bo priskrbela potrebščine, ki bodo preprečevale naključne stike z zdravilom, predvsem z očmi in notranjostjo nosu ter ust.
What is Ledaga and what is it used for?
Kaj je zdravilo Ledaga in za kaj se uporablja?
In addition, a study involving 260 patients found that Ledaga was at least as effective as an ointment containing the same amount of chlormethine.
Poleg tega je študija, ki je vključevala 260 bolnikov, pokazala, da je zdravilo Ledaga vsaj tako učinkovito kot mazilo, ki vsebuje enako količino klormetina.
What benefits of Ledaga have been shown in studies?
Kakšne koristi je zdravilo Ledaga izkazalo v študijah?
The Committee recommended that Ledaga be approved for use in the EU.
Priporočil je, da se zdravilo Ledaga odobri za uporabo v EU.
It is not intended to provide practical advice on how to use Ledaga.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
As a result, cancer cells cannot divide and they eventually die.
Rakave celice se tako ne morejo deliti in posledično odmrejo.
Treatment with Ledaga should be started by a doctor with appropriate experience.
Zdravljenje z zdravilom Ledaga mora uvesti zdravnik z ustreznimi izkušnjami.
Because the number of patients with this skin cancer is low, the disease is considered ‘rare', and Ledaga was designated an ‘orphan medicine' (a medicine used in rare diseases) on 22 May 2012.
Ker je bolnikov s tem kožnim rakom malo, velja ta bolezen za redko, zato je bilo zdravilo Ledaga 22. maja 2012 določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni).
Other information about Ledaga
Druge informacije o zdravilu Ledaga
Ledaga is a ‘hybrid medicine'.
Zdravilo Ledaga je „hibridno zdravilo“.
The summary of the opinion of the Committee for Orphan Medicinal Products for Ledaga can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Povzetek mnenja Odbora za zdravila sirote o zdravilu Ledaga je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Why is Ledaga approved?
Zakaj je bilo zdravilo Ledaga odobreno?
The materials will include a sealable, child-resistant plastic bag for safely storing the medicine in a refrigerator, together with a patient alert card with instructions on the correct way to apply the medicine.
Te potrebščine bodo vključevale plastično vrečko za varno shranjevanje zdravila v hladilniku, ki jo bo mogoče zatesniti in bo varna za otroke, ter opozorilno kartico za bolnika z navodili, kako pravilno uporabljati zdravilo.
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Ledaga has shown comparable safety and effectiveness to Caryolysine and has shown satisfactory quality.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da je zdravilo Ledaga pokazalo primerljivo raven varnosti in učinkovitosti kot zdravilo Caryolysine in zadovoljivo kakovost.
For more information about treatment with Ledaga, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Ledaga preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ledaga have also been included in the summary of product characteristics and the package leaflet.
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Ledaga upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
The full EPAR for Ledaga can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Ledaga je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
For practical information about using Ledaga, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila Ledaga naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
The ointment's effectiveness was considered comparable to that of the reference medicine, Caryolysine.
Učinkovitost mazila je bila primerljiva z učinkovitostjo referenčnega zdravila Caryolysine.
The company provided data from the published literature showing that chlormethine, the active substance in Ledaga, is effective in treating mycosis fungoides-type cutaneous T-cell lymphoma.
Družba je predstavila podatke iz objavljene literature, ki kažejo, da je klormetin, zdravilna učinkovina v zdravilu Ledaga, učinkovit pri zdravljenju kožnega T-celičnega limfoma vrste mycosis fungoides.
The difference between Ledaga and Caryolysine is that Ledaga is available as a gel and Caryolysine was available as a liquid for diluting before applying to the skin.
Razlika med zdraviloma Ledaga in Caryolysine je v tem, da je zdravilo Ledaga na voljo kot gel, zdravilo Caryolysine pa kot tekočina, ki se jo pred nanosom na kožo razredči.
How is Ledaga used?
Kako se zdravilo Ledaga uporablja?
Therefore, the CHMP's view was that, as for Caryolysine, the benefits outweigh the identified risks.
Zato je menil, da njegove koristi enako kot pri zdravilu Caryolysine odtehtajo znana tveganja.
Ledaga is a medicine used to treat adults with a skin cancer called mycosis fungoides-type cutaneous T-cell lymphoma.
Ledaga je zdravilo, ki se uporablja za zdravljenje kožnega T-celičnega limfoma vrste mycosis fungoides pri odraslih.
The active substance in Ledaga, chlormethine, belongs to the group of cancer medicines called ‘alkylating agents'.
Zdravilna učinkovina zdravila Ledaga, klormetin, spada v skupino zdravil proti raku, ki so znane kot alkilirajoče učinkovine.
The medicine contains the active substance chlormethine.
Zdravilo Ledaga vsebuje zdravilno učinkovino klormetin.
Ledaga can only be obtained with a prescription.
Predpisovanje in izdaja zdravila Ledaga je le na recept.
Ledaga, which is available as a gel, is applied as a thin film to the affected areas of the skin once a day.
Tanko plast zdravila Ledaga, ki je na voljo kot gel, se nanese na prizadete dele kože enkrat na dan. Treba ga je nanesti previdno, da ne doseže delov kože, ki jih bolezen ni prizadela.
How does Ledaga work?
Kako zdravilo Ledaga deluje?
• Take your capsule at about the same time each day.
• Kapsulo vzemite vsak dan približno ob istem času.
*Event refers to disease progression or death due to any reason.
* Izraz dogodek se nanaša na napredovanje bolezni ali smrt iz kateregakoli vzroka.
• has menstruated at any time during the previous 12 consecutive months,
• je imela menstruacijo kadarkoli v zadnjih zaporednih 12 mesecih,
Tell your doctor if you notice any changes in your skin.
Povejte svojemu zdravniku, če opazite kakršnekoli spremembe na koži.
These can alert your doctor to possible changes in the function of some parts of your body, for example:
To lahko vašega zdravnika opozori na morebitne spremembe delovanja nekaterih organov, na primer:
This interaction is not expected to be clinically significant.
Navedena interakcija predvidoma ni klinično pomembna.
- Never give this medicine to anyone else.
- Tega zdravila nikoli ne dajajte komu drugemu.
• disturbed sense of taste or strange taste in the mouth
• motnje okušanja ali nenavaden okus v ustih